Brief: Sino Biopharmaceutical Enters Exclusive Cooperation Agreement With Delova Biotech For QP001
06/03/2025 14:37
March 6 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK: ENTERING INTO AN EXCLUSIVE COOPERATION AGREEMENT WITH DELOVA BIOTECH FOR QP001 EXPECTS THAT PRODUCT WILL BE APPROVED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHINA FOR MARKETING IN NEAR FUTURE Further company coverage: 1177.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up